Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A recurrent mutation in PALB2 in Finnish cancer families.
Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. Erkko H, et al. Among authors: kallioniemi a. Nature. 2007 Mar 15;446(7133):316-9. doi: 10.1038/nature05609. Epub 2007 Feb 7. Nature. 2007. PMID: 17287723
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
Honrado E, Osorio A, Palacios J, Milne RL, Sánchez L, Díez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkilä P, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benítez J. Honrado E, et al. Among authors: kallioniemi a. J Clin Oncol. 2005 Oct 20;23(30):7503-11. doi: 10.1200/JCO.2005.01.3698. J Clin Oncol. 2005. PMID: 16234517
Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Karppinen SM, Barkardottir RB, Backenhorn K, Sydenham T, Syrjäkoski K, Schleutker J, Ikonen T, Pylkäs K, Rapakko K, Erkko H, Johannesdottir G, Gerdes AM, Thomassen M, Agnarsson BA, Grip M, Kallioniemi A, Kere J, Aaltonen LA, Arason A, Møller P, Kruse TA, Borg A, Winqvist R. Karppinen SM, et al. Among authors: kallioniemi a. J Med Genet. 2006 Nov;43(11):856-62. doi: 10.1136/jmg.2006.041731. Epub 2006 Jul 6. J Med Genet. 2006. PMID: 16825437 Free PMC article.
Large genomic BRCA2 rearrangements and male breast cancer.
Karhu R, Laurila E, Kallioniemi A, Syrjäkoski K. Karhu R, et al. Among authors: kallioniemi a. Cancer Detect Prev. 2006;30(6):530-4. doi: 10.1016/j.cdp.2006.10.002. Epub 2006 Nov 20. Cancer Detect Prev. 2006. PMID: 17113724
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomäki K, von Smitten K, Heikkilä P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H. Fagerholm R, et al. Among authors: kallioniemi a. Nat Genet. 2008 Jul;40(7):844-53. doi: 10.1038/ng.155. Epub 2008 May 30. Nat Genet. 2008. PMID: 18511948
Penetrance analysis of the PALB2 c.1592delT founder mutation.
Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, Pylkäs K, Southey MC, Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston DM, Winqvist R, Hopper JL. Erkko H, et al. Among authors: kallioniemi a. Clin Cancer Res. 2008 Jul 15;14(14):4667-71. doi: 10.1158/1078-0432.CCR-08-0210. Clin Cancer Res. 2008. PMID: 18628482
RAD51C is a susceptibility gene for ovarian cancer.
Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K, Bützow R, Nevanlinna H. Pelttari LM, et al. Among authors: kallioniemi a. Hum Mol Genet. 2011 Aug 15;20(16):3278-88. doi: 10.1093/hmg/ddr229. Epub 2011 May 25. Hum Mol Genet. 2011. PMID: 21616938
142 results